The Cardiovascular Research Foundation (CRF®) has unveiled an extraordinary lineup of groundbreaking studies slated for presentation at the forthcoming New York Valves: The Structural Heart Summit™, scheduled for June 24-26, 2026. This premier event, hosted at the Jacob K. Javits Convention Center in New York City, brings together leading interventional cardiologists, cardiac surgeons, and clinical researchers to showcase transformative advancements in the treatment of structural heart disease. The summit’s scientific agenda features an impressive array of 22 late-breaking clinical science presentations alongside eight pioneering innovation reports, each promising to reshape the landscape of valvular therapy.
Central to the conference’s late-breaking clinical studies is the burgeoning field of transcatheter aortic valve replacement (TAVR), a minimally invasive procedure that has revolutionized the management of aortic stenosis. The research to be shared includes long-term valve durability data, extending as far as seven to eight years in pivotal trials such as PARTNER 3 and studies involving the Evolut Platform. These data represent some of the first comprehensive, extended durability assessments of bioprosthetic valves implanted via catheter-based methods, providing critical insights into valve longevity, risks of reintervention, and patient outcomes beyond the mid-term horizon.
Low-risk patients treated with balloon-expandable valves, a subgroup historically managed with surgical valve replacement, will be a particular focus. The anticipated findings from U.S.-based studies underscore the expanding applicability of TAVR beyond traditional high-risk cohorts, reflecting a paradigm shift in patient selection. Detailed analyses have also explored outcomes in bicuspid aortic valve disease—a congenital malformation often excluded from early TAVR trials—spotlighting the nuanced considerations necessary when applying transcatheter therapies to anatomically complex cases.
Further expanding the scope of the summit are significant investigations into tricuspid valve disease, an often underappreciated yet clinically impactful valvular pathology. Presentations will delve into the use of transcatheter tricuspid valve replacement (TTVR) following failed transcatheter tricuspid valve repair (T-TEER), revealing pooled registry data that illuminate procedural efficacy and safety. Additionally, outcomes from patient cohorts deemed ineligible for TRISCEND trials and insights into valve thrombosis post-TTVR will enrich the collective understanding of this burgeoning frontier.
The mitral valve, with its intricate anatomy and diverse pathology, also anchors several late-breaking sessions. Cutting-edge data from the ENCIRCLE-MAC study will share one-year outcomes of transcatheter mitral valve replacement (TMVR) in patients burdened with severe mitral annular calcification—a notoriously challenging subset. Registry analyses comparing the efficacy of M-TEER devices such as MitraClip and PASCAL promise to refine interventional choices, while investigations into repeat interventions and the novel REPAIR study address previously unmet clinical challenges, including treatment in patients with small mitral valve orifice areas.
Innovation sessions will spotlight revolutionary technological advancements. AI-augmented electrocardiographic analysis emerges as a powerful tool for early detection and prognostication of structural heart disease, potentially enabling earlier intervention and personalized management strategies. Discussions will also cover the evolution of multidisciplinary heart valve teams, emphasizing patient-centered care models across leading TAVR programs. Novel devices such as leaflet modification tools designed for valve-in-valve TAVR procedures are expected to demonstrate enhanced procedural safety and efficacy.
On the final day, focused sessions revisit TAVR with studies assessing baseline clinical and echocardiographic traits of moderate aortic stenosis patients enrolled in the PROGRESS trial, and large-scale quality metrics from the American Heart Association’s Target AS Initiative. Efforts to standardize care pathways facilitated by electronic health records (EHR) will be discussed, signaling a move towards integrated, data-driven patient management. Procedural nuances, including vascular access site selection and new pacemaker implantation risks post-TAVR for pure aortic regurgitation, will be evaluated with the rigor befitting large multicenter cohorts.
Innovation tracks will introduce the first multicenter experiences utilizing pulsed field ablation of the left atrial appendage (LAA) prior to LAA closure, aiming to mitigate peri-device leaks—a known postprocedural complication. Comparative registries investigating M-TEER versus valve-in-ring approaches for failed surgical mitral valve repair will enrich decision-making algorithms. Furthermore, the anticipated SMART-MAC trial will elucidate outcomes of mitral valve lithotripsy using specialized balloon techniques to address severe annular calcification—a technical challenge limiting current therapies. Ingenious registry data on TAVR with the JenaValve Trilogy system in patients supported by continuous-flow left ventricular assist devices (LVADs) confront the intersection of mechanical circulatory support and valvular interventions.
Beyond research presentations, New York Valves 2026 promises a compelling blend of live procedural demonstrations from world-renowned operators, over 180 scientific abstracts, and more than 220 challenging clinical case reviews. The event’s comprehensive educational scope also encompasses the second annual LAAC Summit, dedicated to left atrial appendage closure with pragmatic discussions and case-based learning. Collectively, these offerings foster an environment conducive to innovation dissemination and clinical excellence.
The CRF® maintains its stature as a vanguard institution in interventional cardiovascular medicine, fostering advancements through its Skirball Center for Innovation, Clinical Trials Center, Center for Education, CRF Digital platform, TCTMD®, and its dedicated journal, Structural Heart: The Journal of the Heart Team. The forthcoming summit epitomizes CRF’s commitment to accelerating cardiovascular breakthroughs and equipping clinicians worldwide with evidence-based tools to improve patient survival and quality of life.
For press inquiries and registration details, media professionals are encouraged to contact Judy Romero at [email protected]. The New York Valves: The Structural Heart Summit stands as an unmissable convergence of clinical genius and technological innovation, poised to redefine standards of care in structural heart disease management for years to come.
Subject of Research: Structural Heart Disease and Transcatheter Valve Therapy
Article Title: Breakthroughs in Transcatheter Valve Replacement Unveiled at New York Valves 2026
News Publication Date: June 2, 2026
Web References:
https://www.nyvalvesconference.com/
http://www.crf.org
Keywords: Structural heart disease, TAVR, TMVR, tricuspid valve replacement, valve durability, mitral annular calcification, AI ECG analysis, valve thrombosis, pulsed field ablation, left atrial appendage closure, valve-in-valve therapy, cardiovascular innovation
Tags: balloon-expandable valve patient outcomesbioprosthetic valve durability datacardiovascular research foundation eventEvolut Platform clinical outcomeslate-breaking clinical studies in cardiologylong-term valve performance studiesminimally invasive aortic stenosis treatmentNew York Valves 2026 conferencePARTNER 3 trial resultsstructural heart disease researchtranscatheter aortic valve replacement advancementsvalvular therapy innovations 2026
